Bristol-Myers Squibb: Pancreatic Neoplasms trials

The registry lists 21 Pancreatic Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 10Phase 2 11Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingNCT07492680Phase 2
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT07223047Phase 1/2
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionRecruitingNCT05245500Phase 1
• A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedNCT03336216Phase 2Results posted
• A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCompletedNCT03184870Phase 1/2Results posted
• Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)CompletedNCT02301143Phase 2Results posted
• Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic CancerCompletedNCT02017015Phase 2Results posted
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)CompletedNCT01964430Phase 3Results posted
• Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic CancerCompletedNCT00398086Phase 1/2Results posted
• A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid TumorsCompletedNCT00379639Phase 1Results posted
• MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00112580Phase 2Results posted
• A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)Active, not recruitingNCT07076121Phase 2/3
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2
• A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic CancerTerminatedNCT02670746
• Treatment of Pancreatic Cancer With AbraxaneCompletedNCT02555813
• Observational Study of Quality of Live in Patients With Metastatic Pancreatic CancerCompletedNCT02342847
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic HyperbilirubinemiaTerminatedNCT02267707Phase 1
• A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.CompletedNCT02021500
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the PancreasTerminatedNCT00179751Phase 1/2